Vertex Completes $10B Acquisition of Crinetics; CRNX to Be Delisted
CRNX has more than doubled off its 52-week low of $30.25 on elevated volume (2.0× avg).
Summary
Vertex Pharmaceuticals completed its $10 billion all-cash acquisition of Crinetics on September 1, 2026. Each CRNX share was converted into $85.00 in cash, and the stock will be delisted from Nasdaq.
Key Events · M&A and Partnerships · CRNX
-
Merger Closed
Merger Sub merged into Crinetics on September 1, 2026, making Crinetics a wholly owned subsidiary of Vertex Pharmaceuticals. Each outstanding share was converted into the right to receive $85.00 in cash.
-
$10B Consideration Funded
Vertex paid approximately $10.0 billion in aggregate consideration, funded with cash on hand and borrowings under Vertex's term loan credit agreement.
-
Nasdaq Delisting Initiated
Crinetics requested Nasdaq suspend trading and file Form 25 to delist CRNX. The company will file Form 15 to terminate SEC registration and suspend reporting obligations under Sections 13 and 15(d).
-
Board and Officers Replaced
All eight incumbent directors resigned. Charles Wagner became sole director and President of the surviving corporation; Prasanna Thombre (Treasurer) and Omar White (Secretary) were appointed.
Analysis · CRNX · Life Sciences
The Vertex acquisition of Crinetics closed on September 1, 2026, converting each outstanding share into $85.00 in cash. Vertex funded the approximately $10.0 billion consideration with cash on hand and term loan borrowings. Nasdaq has been asked to delist CRNX, and the company will file a Form 15 to terminate its SEC registration and suspend reporting obligations. All incumbent directors resigned, replaced by Vertex personnel — Charles Wagner as sole director and President. This is the final step in a deal announced July 6, 2026, and it ends Crinetics' existence as an independent public company.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 578 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRNX was trading at $84.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9B. The 52-week trading range was $30.25 to $85.01. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.